{"id":"cdk4-6i","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Leukopenia"},{"rate":"20-40","effect":"Anemia"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3891096","moleculeType":"Small molecule","molecularWeight":"436.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CDK4/6 inhibitors are small molecules that bind to and inhibit cyclin-dependent kinases 4 and 6, key regulators of the G1/S cell cycle checkpoint. By preventing the phosphorylation of retinoblastoma (Rb) protein, these inhibitors trap cancer cells in G1 phase, preventing their progression to S phase and DNA replication. This mechanism is particularly effective in hormone receptor-positive breast cancers and other malignancies with dysregulated cell cycle control.","oneSentence":"CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression in G1 phase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:04.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy)"},{"name":"Other CDK4/6-dependent malignancies in clinical development"}]},"trialDetails":[{"nctId":"NCT07492641","phase":"PHASE3","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-05-11","conditions":"HR+/HER2- Breast Cancer","enrollment":1056},{"nctId":"NCT07085767","phase":"PHASE3","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2025-11-03","conditions":"Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":1000},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":"Locally Advanced (Inoperable) or Metastatic Breast Cancer","enrollment":895},{"nctId":"NCT07029399","phase":"PHASE1","title":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"NiKang Therapeutics, Inc.","startDate":"2025-03-25","conditions":"HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors","enrollment":205},{"nctId":"NCT06065748","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-11","conditions":"Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer","enrollment":1050},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT06790693","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-09","conditions":"Breast Cancer","enrollment":450},{"nctId":"NCT07446686","phase":"EARLY_PHASE1","title":"Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guizhou Provincial People's Hospital","startDate":"2026-04-01","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT05646862","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-07","conditions":"Breast Cancer","enrollment":420},{"nctId":"NCT07019363","phase":"PHASE3","title":"CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1903},{"nctId":"NCT06666439","phase":"","title":"Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer","status":"RECRUITING","sponsor":"Julia Foldi","startDate":"2024-12-12","conditions":"Metastatic Invasive Lobular Carcinoma (mILC)","enrollment":20},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT07235176","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Advanced ER+/HER2- Breast Cancer","enrollment":300},{"nctId":"NCT05563220","phase":"PHASE1, PHASE2","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2023-01-24","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":435},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT05977036","phase":"NA","title":"BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-09-25","conditions":"Metastatic Breast Cancer, Unresectable Breast Cancer","enrollment":65},{"nctId":"NCT07273357","phase":"","title":"Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening","status":"NOT_YET_RECRUITING","sponsor":"Region Jönköping County","startDate":"2026-04-01","conditions":"Geriatric Assessment, Adjuvant Drug Therapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":200},{"nctId":"NCT05252416","phase":"PHASE1","title":"(VELA) Study of BLU-222 in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Blueprint Medicines Corporation","startDate":"2022-04-07","conditions":"Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification","enrollment":50},{"nctId":"NCT06572800","phase":"NA","title":"Tka Assay for CDK4/6i","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-09-05","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma","enrollment":34},{"nctId":"NCT06975371","phase":"","title":"Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-04-14","conditions":"Advanced/Metastatic HER2-negative Breast Cancer","enrollment":1415},{"nctId":"NCT07190651","phase":"","title":"Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-10-01","conditions":"Breast Cancer, CDK4/6 Inhibitor","enrollment":50},{"nctId":"NCT05735080","phase":"PHASE1, PHASE2","title":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","status":"RECRUITING","sponsor":"Incyclix Bio","startDate":"2023-03-28","conditions":"Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor","enrollment":150},{"nctId":"NCT07148505","phase":"","title":"A Study of Real-world Outcomes Among Patients Treated With Ribociclib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-24","conditions":"Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT03439735","phase":"PHASE2","title":"Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-07-20","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT05173103","phase":"","title":"Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2021-09-24","conditions":"Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer","enrollment":254},{"nctId":"NCT07073755","phase":"","title":"Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2023-01-01","conditions":"Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer","enrollment":200},{"nctId":"NCT07012720","phase":"NA","title":"Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-04-01","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT06996093","phase":"PHASE3","title":"Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-02","conditions":"Breast Cancer","enrollment":2508},{"nctId":"NCT06882499","phase":"NA","title":"Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II","status":"NOT_YET_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2025-05-01","conditions":"Breast Cancer, Metastatic, Metastatic Breast Cancer","enrollment":74},{"nctId":"NCT06805812","phase":"","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-05-01","conditions":"Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic","enrollment":3500},{"nctId":"NCT06535828","phase":"","title":"AIM4 AI and Mechanistic Modeling in Molecular Medicine","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-30","conditions":"Molecular Medicine","enrollment":""},{"nctId":"NCT05953350","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-11-07","conditions":"Inhibition of Autophagy Synergizes Anti-tumor Effect","enrollment":29},{"nctId":"NCT06613373","phase":"PHASE4","title":"An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","startDate":"2024-10-15","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT06558084","phase":"","title":"Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-07-06","conditions":"Toxicity, Drug, Progression, Disease","enrollment":64},{"nctId":"NCT05770713","phase":"","title":"A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-12","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT06447623","phase":"PHASE3","title":"Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-02-01","conditions":"Advanced Breast Cancer, HR+/HER2- Breast Cancer","enrollment":184},{"nctId":"NCT05361655","phase":"","title":"Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-01","conditions":"Metastatic Breast Cancer","enrollment":2888},{"nctId":"NCT01953926","phase":"PHASE2","title":"Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","status":"TERMINATED","sponsor":"Puma Biotechnology, Inc.","startDate":"2013-09-30","conditions":"Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","enrollment":582},{"nctId":"NCT04396626","phase":"","title":"HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes","status":"TERMINATED","sponsor":"Pfizer","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":975},{"nctId":"NCT05809024","phase":"PHASE4","title":"Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy","status":"UNKNOWN","sponsor":"Yongsheng Wang","startDate":"2023-03-01","conditions":"Locally Advanced Breast Cancer, Hormone Receptor Positive，HER2-negative Breast Cancer","enrollment":100},{"nctId":"NCT05806671","phase":"PHASE2","title":"Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT05153135","phase":"","title":"Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-05-08","conditions":"Metastatic Breast Cancer","enrollment":4320},{"nctId":"NCT05141240","phase":"","title":"A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-04-15","conditions":"Metastatic Breast Cancer","enrollment":4650}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CDK4/6i","genericName":"CDK4/6i","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDK4/6 inhibitors block cyclin-dependent kinases 4 and 6, which prevents phosphorylation of the retinoblastoma protein and halts cell cycle progression in G1 phase. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (in combination with endocrine therapy), Other CDK4/6-dependent malignancies in clinical development.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}